SCHEMBL7118367

SCHEMBL7118367

CC(C)(C)COS(=O)(=O)c1ccccc1Oc1c(N)cccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCHE P06276 6/20 0.36
ACHE P22303 6/20 0.36
KCNH2 Q12809 1/20 0.34
NFE2L2 Q16236 1/20 0.34
HTR6 P50406 1/20 0.33
CCR4 P51679 1/20 0.32
P2RX4 Q99571 2/20 0.32
GAA P10253 2/20 0.31
SSTR1 P30872 1/20 0.31
SSTR4 P31391 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
APEX1 P27695 1/20 0.31
DPP4 P27487 1/20 0.31
CCR2 P41597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118221 0.81 BCHE (0.45) BCHEACHEMAPTAPEX1
SCHEMBL7192886 0.78 TTR (0.45) BCHEACHEKCNH2NFE2L2P2RX4
SCHEMBL197116 0.77 HSD11B1 (0.44) KCNH2NFE2L2HTR6CCR4GAA
SCHEMBL7615016 0.75 APEX1 (0.58) BCHEACHEGAAMAPTAPEX1
SCHEMBL27857418 0.74 CCR4 (0.47) CCR4
SCHEMBL811172 0.67 ALDH1A1 (0.35) HTR6KDM4EMAPTL3MBTL1
SCHEMBL11096653 0.67 KDM4E (0.59) BCHEACHEGAAKDM4EMAPT
SCHEMBL27502680 0.67 BCHE (0.44) BCHEACHEGAAKDM4EMAPT
SCHEMBL7115582 0.66 APEX1 (0.64) GAAMAPTL3MBTL1APEX1
SCHEMBL8712194 0.66 HSD11B1 (0.43) KCNH2NFE2L2HTR6GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM BCHE 1255/4885ACHE 1054/4885KCNH2 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.